The asthma market in the EU5 is highly competitive. A large number of approved agents are available including maintenance therapies—LABA/ICSFDC (e.g., GSK’s Seretide and Relvar, AstraZeneca’s Symbicort, branded generic and generic salmeterol/fluticasone), ICSs (e.g., AstraZeneca’s Pulmicort, Teva’s Qvar), leukotriene inhibitors, biologics (e.g., Novartis’s Xolair, GSK’s Nucala), and a LAMA (Boehringer Ingelheim’s Spiriva, generics)—as well as rescue treatments, such as SABAs (e.g., GSK’s Ventolin). Understanding patient pathways and drivers of treatment decision for key players in the market can help optimize uptake of these agents and provide valuable insights for manufacturers of novel brands coming to the market.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
Geographies: EU5 (France, Germany, Italy, Spain, United Kingdom)
Primary research: Survey of approximately 250 pulmonologists in the EU5
Key drugs covered: Seretide, Symbicort, Relvar, Formodual/Foster, Flutiform, Spiriva, Xolair, Nucala, Cinqaero, montelukast
Key insights provided: